Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units... Show more
BDX broke above its upper Bollinger Band on March 18, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 49 similar instances where the stock broke above the upper band. In of the 49 cases the stock fell afterwards. This puts the odds of success at .
The Momentum Indicator moved below the 0 level on April 01, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BDX as a result. In of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for BDX turned negative on April 02, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
BDX moved below its 50-day moving average on March 21, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BDX entered a downward trend on March 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BDX advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.783) is normal, around the industry mean (23.715). P/E Ratio (55.975) is within average values for comparable stocks, (83.458). Projected Growth (PEG Ratio) (1.305) is also within normal values, averaging (5.667). Dividend Yield (0.015) settles around the average of (0.018) among similar stocks. P/S Ratio (3.630) is also within normal values, averaging (41.612).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a manufacturer of medical supplies, devices, laboratory equipment and diagnostic products
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with HOLX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then HOLX could also see price increases.
Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
---|---|---|---|---|
BDX | 100% | +0.17% | ||
HOLX - BDX | 52% Loosely correlated | -1.34% | ||
STE - BDX | 47% Loosely correlated | +0.82% | ||
ZBH - BDX | 42% Loosely correlated | +0.12% | ||
MDT - BDX | 39% Loosely correlated | +0.42% | ||
CNMD - BDX | 39% Loosely correlated | +1.73% | ||
More |